146 results on '"Gregersen, Henrik"'
Search Results
2. Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission – results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial
3. Strategies to improve patient-reported outcome completion rates in longitudinal studies
4. Anti-Tr/DNER antibody paraneoplastic cerebellar degeneration preceding a very late relapse of Hodgkin Lymphoma after 12 years
5. Incidence and clinical characteristics of multiple myeloma with low M-protein levels and normal values of hemoglobin, creatinine, calcium, and serum free light chain ratio
6. The majority of newly diagnosed myeloma patients do not fulfill the inclusion criteria in clinical phase III trials
7. A randomized placebo-controlled phase II study of clarithromycin or placebo combined with VCD induction therapy prior to high-dose melphalan with stem cell support in patients with newly diagnosed multiple myeloma
8. Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial
9. Geographical and ecological analyses of multiple myeloma in Denmark: Identification of potential hotspot areas and impact of urbanisation.
10. Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial
11. Causes of early death in multiple myeloma patients who are ineligible for high-dose therapy with hematopoietic stem cell support: A study based on the nationwide Danish Myeloma Database
12. Polymorphisms in the heparanase gene in multiple myeloma association with bone morbidity and survival
13. P-050 GEN3014 (HexaBody-CD38) versus daratumumab in patients with relapsed/ refractory multiple myeloma: design of randomized head-to-head expansion cohort of phase 1/2 trial
14. Single nucleotide polymorphisms in the promoter region of the IL1B gene influence outcome in multiple myeloma patients treated with high-dose chemotherapy independently of relapse treatment with thalidomide and bortezomib
15. The importance of a sub-region on chromosome 19q13.3 for prognosis of multiple myeloma patients after high-dose treatment and stem cell support: a linkage disequilibrium mapping in RAI and CD3EAP
16. Genetic variants in the P2RX7 gene are associated with risk of multiple myeloma
17. Outcome data from >10 000 multiple myeloma patients in the Danish and Swedish national registries.
18. Vascular endothelial growth factor (VEGF) gene polymorphisms may influence the efficacy of thalidomide in multiple myeloma
19. Monoclonal gammopathy of undetermined significance and risk of venous thromboembolism
20. Improved survival of multiple myeloma patients with late relapse after high-dose treatment and stem cell support, a population-based study of 348 patients in Denmark in 1994–2004
21. UK Myeloma Forum (UKMF) and Nordic Myeloma Study Group (NMSG): guidelines for the investigation of newly detected M-proteins and the management of monoclonal gammopathy of undetermined significance (MGUS)
22. Carfilzomib and dexamethasone maintenance following salvage ASCT in multiple myeloma: A randomised phase 2 trial by the Nordic Myeloma Study Group.
23. Consolidation and Maintenance in Newly Diagnosed Multiple Myeloma.
24. Preliminary Dose-Escalation Results from a Phase 1/2 Study of GEN3014 (HexaBody®-CD38) in Patients (pts) with Relapsed or Refractory Multiple Myeloma (RRMM)
25. Fracture risk in patients with monoclonal gammopathy of undetermined significance
26. Autoimmune and Chronic Inflammatory Disorders and Risk of Non-Hodgkin Lymphoma by Subtype
27. PROGNOSIS OF ALL IN 10-20 YEAR OLD PATIENTS IN DENMARK 1992-2001: P.S.001
28. Outcome of treatment with carfilzomib before and after treatment with daratumumab in relapsed or refractory multiple myeloma patients.
29. Direct costs of antineoplastic and supportive treatment for progressive multiple myeloma in a tax-based health system.
30. Multiple myeloma following an episode of community-acquired pneumococcal bacteraemia or meningitis
31. Mortality and causes of death in patients with monoclonal gammopathy of undetermined significance
32. Comorbidities in multiple myeloma and implications on survival: A population‐based study.
33. Socioeconomic Status and Overall Survival Among Patients With Hematological Malignant Neoplasms.
34. No influence of the polymorphisms CYP2C19 and CYP2D6 on the efficacy of cyclophosphamide, thalidomide, and bortezomib in patients with Multiple Myeloma
35. The risk of bacteremia in patients with monoclonal gammopathy of undetermined significance
36. Validation of the UK myeloma research alliance risk profile, a new clinical prediction model for outcome in patients with newly diagnosed multiple myeloma not eligible for autologous stem cell transplantation; a population‐based study from the Danish national multiple myeloma registry
37. P817: VALIDATION OF THE SECOND REVISED INTERNATIONAL STAGING SYSTEM (R2‐ISS) IN A LARGE POPULATION‐BASED, NATIONWIDE COHORT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA.
38. Extracellular vesicle-associated procoagulant phospholipid and tissue factor activity in multiple myeloma.
39. Clarithromycin added to bortezomib‐cyclophosphamide‐dexamethasone impairs health‐related quality of life in multiple myeloma patients.
40. P1671: CARFILZOMIB-DEXAMETHASONE MAINTENANCE HAMPERS RECOVERY AFTER SALVAGE AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH MULTIPLE MYELOMA.
41. The impact of comorbidity on mortality in multiple myeloma: a Danish nationwide population-based study.
42. The Danish National Multiple Myeloma Registry.
43. Smoldering multiple myeloma risk factors for progression: a Danish population-based cohort study.
44. Data quality of the monoclonal gammopathy of undetermined significance diagnosis in a hospital registry.
45. Survival of cancer patients with prior monoclonal gammopathy of undetermined significance
46. No influence of the polymorphisms CYP2C19 and CYP2D6 on the efficacy of cyclophosphamide, thalidomide, and bortezomib in patients with Multiple Myeloma.
47. Cancer risk in patients with monoclonal gammopathy of undetermined significance.
48. A Phase II Study of Bortezomib-Dexametason Followed by High-Dose Melphalan Combined with Bortezomib in Patients Relapsing After High-Dose Melphalan with Autologous Stem Cell Support
49. Non-invasive Archaeology of Skeletal Material by CT Scanning and Three-dimensional Reconstruction.
50. Genetic variants in the P2 RX7 gene are associated with risk of multiple myeloma.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.